To determine whether virus positivity might be a useful marker for response to ICI therapy, we evaluated the correlation of viral status with response to ICI therapy with anti-PD(L)1 in 32 cohorts reported on ClinicalTrials.gov that had available therapy response and virus infection status data, representing four virus-linked cancers (Supplementary Data 18 and Supplementary Data 19). This evidence concerns the gene CD274 and viral infectious disease.